Current Report Filing (8-k)
November 14 2017 - 4:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2017
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
Commission
File
Number: 001-34207
|
|
|
Delaware
|
|
33-0728374
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510)
848-5100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the Registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01.
|
Entry into a Material Definitive Agreement
|
On November 8, 2017, Dynavax
Technologies Corporation (the Company) and inVentiv Commercial Services, LLC (inVentiv, and together with the Company, the Parties) entered into a project agreement (the Project Agreement) pursuant to
that certain Master Services Agreement, by and between the Parties, dated as of January 11, 2016 (the MSA). Pursuant to the Project Agreement, inVentiv will provide a field force of account managers to provide certain detailing
services, sales operation services, compliance services and training services with respect to
HEPLISAV-B
to the Company in exchange for an
up-front
implementation fee
and a fixed annual fee.
The Project Agreement terminates automatically on the second anniversary of the date of the first activity
undertaken by inVentiv to detail
HEPLISAV-B
(the Deployment Date) unless earlier extended upon the mutual written agreement of the Parties. The Company may terminate the Project Agreement for any
reason upon timely notice; provided, however, that if the Company terminates the Project Agreement prior to the first anniversary of the Deployment Date, the Company will be obligated to pay inVentiv a termination fee, the amount of which varies
depending on the date of termination.
The foregoing summary of the Project Agreement is not complete and is qualified in its entirety by
reference to the Project Agreement and the MSA, which will be filed as exhibits to the Companys Annual Report on Form
10-K
for the year ending December 31, 2017. Certain terms of the Project
Agreement have been omitted from this Form
8-K
and will be omitted from the version to be filed as an exhibit to the Form
10-K
pursuant to a Confidential Treatment
Request that the Company plans to submit to the Securities and Exchange Commission at the time of the filing of the Form
10-K.
On November 9, 2017, the Company issued a press release titled
Dynavax Announces FDA Approval of
HEPLISAV-B
TM
for Prevention of Hepatitis B in Adults. A copy of the press release is attached as Exhibit 99.1
to this current report and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits. The following exhibit is filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Dynavax Technologies Corporation
|
|
|
|
|
|
|
|
|
|
|
|
Date: November 14, 2017
|
|
|
|
By:
|
|
/s/ STEVEN N. GERSTEN
|
|
|
|
|
|
|
Steven N. Gersten
|
|
|
|
|
|
|
Vice President, General Counsel and Chief Ethics and Compliance Officer
|
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024